ChemoCentryx Stock News

The short- and long-term outlook is good, but mid-term risks are high. Here's what you can do now. Top sectors and stocks you ought to be considering for portfo

We wouldn't blame ChemoCentryx, Inc. (NASDAQ:CCXI) shareholders if they were a little worried about the fact that...

Yesterday, a Director at ChemoCentryx (CCXI), Geoffrey Parker, sold shares of CCXI for $1.1M. Following Geoffrey Parker's last CCXI Sell transaction on

BidaskClub downgraded shares of ChemoCentryx (NASDAQ:CCXI) from a strong-buy rating to a buy rating in a report published on Thursday morning, BidAskClub reports. Several other analysts also recently

Encouraging signs emerge, but stock-picking is key. Top large-cap, mid-cap, and small-cap sectors and stocks now. Plan for ongoing volatility, and watch for eme

Citigroup Inc. lifted its holdings in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 446.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund o

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

Phoenix Tree (NASDAQ:IMAB) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recom

ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

ChemoCentryx Inc (NASDAQ:CCXI) – Analysts at SVB Leerink increased their Q1 2020 earnings per share estimates for ChemoCentryx in a research note issued on Wednesday, March 11th. SVB Leerink analyst

Charles Schwab Investment Management Inc. boosted its position in ChemoCentryx Inc (NASDAQ:CCXI) by 3.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 100,310 sh

SVB Leerink reiterated their outperform rating on shares of ChemoCentryx (NASDAQ:CCXI) in a research report sent to investors on Wednesday, Zacks.com reports. Several other brokerages also recently is

ChemoCentryx Inc (NASDAQ:CCXI) – Investment analysts at Piper Sandler issued their Q1 2020 earnings per share (EPS) estimates for shares of ChemoCentryx in a report issued on Tuesday, March 10th. Pi

Full Year 2019 Vifor Pharma AG Earnings Call